November 22, 2024

Millions in federal funding: customized 3D printing for patients in oral and maxillofacial surgery

Millions in federal funding: customized 3D printing for patients in oral and maxillofacial surgery

The German Federal Ministry of Education and Research (BMBF) is currently funding a project at the Department of Oral and Maxillofacial Surgery at Heidelberg University Hospital (UKHD) with around 1.2 million euros. The aim is to use 3D printing technology to produce individualized implants directly in the clinic, thus enabling faster, more efficient and more precise patient-specific care. To this end, the UKHD is working with an industrial partner.

The ADDIFEM project (Optimized clinical patient care at the point of care through individualized implants using 3D printing technology) aims to significantly improve the care of patients with complex midface fractures and in reconstructive, oncological and malformation-correcting surgery. To this end, state-of-the-art 3D printing technology is being installed to produce individualized implants directly in the clinic. Currently, the time-consuming planning and manufacturing process for such implants significantly extends the time to surgery. “BMBF funding for this model project enables close collaboration between industry and clinics to provide our patients with customized implants faster, more efficiently and more precisely, and to shorten innovation cycles,” says Professor Dr. Dr. Dr. h.c. Jürgen Hoffmann, Medical Director of the Department of Oral and Maxillofacial Surgery at the University Hospital Heidelberg (UKHD).

The project is being carried out by the working group led by Dr. Dr. Reinald Kühle, Senior Physician at the Department of Oral and Maxillofacial Surgery at the UKHD, in close collaboration with the medical technology company KLS Martin SE & Co. KG, and is funded under the BMBF funding guideline “Development of industry-in-clinic platforms for the development of innovative medical products”. For the development phase, the team conducting the first subproject received around 2.2 million euros – in addition to the 1.2 million euros from the BMBF, the industrial partner provided around one million euros. For the three subsequent projects, BMBF funding of up to 4.3 million euros plus industry contributions is planned. The funding period will cover a total of three years.

Step by step towards optimized care

In the first project phase, digital planning and implant design will be increasingly automated and optimized in order to manufacture implants on site on a trial basis in the second phase. The integration of an industrial point of care (PoC), i.e. a permanent presence of the cooperating company KLS Martin SE & Co. KG directly in the clinic, should accelerate and optimize these processes. The aim of the current feasibility study is to establish a new, faster manufacturing process for 3D implants, which should then also be approved outside the UKHD.

“With direct planning and on-site production, we expect not only faster patient care, but also greater precision and accuracy of fit of the customized implants, and thus a higher success rate and a lower risk of complications,” says Dr. Dr. Reinald Kühle. The team also expects that the new manufacturing process will use less material and thus be more efficient and cost-effective than conventional methods, especially when using expensive materials such as PEEK (polyether ether ketone). “It is a great opportunity to develop new materials and processes under clinically relevant conditions and to bring them to production maturity with our partner. This also includes joint training of medical personnel and engineers to achieve the best results,” says Dr. Dr. Kühle.

Our latest News

discover more
Globally influential: Professor Auffarth once again on ophthalmology’s “Power List”

Globally influential: Professor Auffarth once again on ophthalmology’s “Power List”

Professor Dr. Gerd Auffarth continues to be one of the world’s leading ophthalmologists, according to “The Ophthalmologist”. The journal has now published its “Power List 2025” of the most influential representatives of the field. The Medical Director of the Eye Clinic at Heidelberg University Hospital (UKHD) has now been named on the list for the […]

3D bioprinting: NMI, TU Darmstadt and Black Drop develop improved bioink

3D bioprinting: NMI, TU Darmstadt and Black Drop develop improved bioink

Joint press release by the NMI and the Technical University of Darmstadt (How) can we 3D print tissues that mimic the complex anatomy of natural body tissue as closely as possible? 3D bioprinting is a great hope in the field of regenerative medicine to produce miniaturized tissues and organ precursors with biological functionality. Today, however, […]

Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies. ZURICH, SWITZERLAND, and BROOKLYN, NEW YORK, USA, April 23, 2025 — VERAXA Biotech AG(“VERAXA” or the “Company”), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp